Astellas Company Profile

What is the competitive landscape for ASTELLAS

ASTELLAS has thirty-seven approved drugs.

There are thirty-one US patents protecting ASTELLAS drugs. There is one tentative approval on ASTELLAS drugs.

There are four hundred and sixty-three patent family members on ASTELLAS drugs in forty-three countries and eighty-one supplementary protection certificates in twenty countries.

Summary for Astellas

International Patents:	463
US Patents:	31
Tradenames:	21
Ingredients:	16
NDAs:	37
Patent Litigation for Astellas:	See patent lawsuits for Astellas

Drugs and US Patents for Astellas

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astellas	CRESEMBA	isavuconazonium sulfate	CAPSULE;ORAL	207500-001	Mar 6, 2015		RX	Yes	Yes
Astellas	ARISTOCORT	triamcinolone diacetate	SYRUP;ORAL	011960-004	Approved Prior to Jan 1, 1982		DISCN	No	No
Astellas	VEOZAH	fezolinetant	TABLET;ORAL	216578-001	May 12, 2023		RX	Yes	Yes	8,871,761			Y
Astellas	XTANDI	enzalutamide	TABLET;ORAL	213674-001	Aug 4, 2020		RX	Yes	No	8,183,274
Astellas	PROGRAF	tacrolimus	CAPSULE;ORAL	050708-003	Aug 24, 1998	AB	RX	Yes	No
Astellas	ADENOSCAN	adenosine	SOLUTION;INTRAVENOUS	020059-001	May 18, 1995		DISCN	Yes	No
Astellas	CYCLOCORT	amcinonide	LOTION;TOPICAL	019729-001	Jun 13, 1988		DISCN	Yes	No

Expired US Patents for Astellas

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astellas	CRESEMBA	isavuconazonium sulfate	CAPSULE;ORAL	207500-002	Nov 22, 2022	10,812,238
Astellas	ASTAGRAF XL	tacrolimus	CAPSULE, EXTENDED RELEASE;ORAL	204096-002	Jul 19, 2013	6,440,458
Astellas	LEXISCAN	regadenoson	SOLUTION;INTRAVENOUS	022161-001	Apr 10, 2008	9,045,519
Astellas	LEXISCAN	regadenoson	SOLUTION;INTRAVENOUS	022161-001	Apr 10, 2008	6,642,210
Astellas	PROGRAF	tacrolimus	INJECTABLE;INJECTION	050709-001	Apr 8, 1994	5,260,301
Astellas	ASTAGRAF XL	tacrolimus	CAPSULE, EXTENDED RELEASE;ORAL	204096-001	Jul 19, 2013	6,884,433
Astellas	LEXISCAN	regadenoson	SOLUTION;INTRAVENOUS	022161-001	Apr 10, 2008	8,536,150

Paragraph IV (Patent) Challenges for ASTELLAS drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Extended-release Capsules	0.5 mg, 1 mg, and 5 mg		2013-11-15
	For Injection	50 mg/vial and 100 mg/vial		2014-06-16
	Injection	3 mg/mL, 20 mL and 30 mL vials		2005-04-16
	Tablets	5 mg and 10 mg		2009-04-08
	Capsules	40 mg		2016-08-31
	Injection	3 mg/mL, 20 mL and 30 mL vials		2005-04-18
	Injection	0.08 mg/mL, 5 mL vial		2012-04-10

International Patents for Astellas Drugs

Country	Patent Number	Estimated Expiration
South Korea	101515335
Japan	5831449
Russian Federation	2008142728
China	105358535
Israel	241473
Portugal	2948455
Spain	2892029

Supplementary Protection Certificates for Astellas Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1893196	C01893196/01	Switzerland		PRODUCT NAME: ENZALUTAMID; REGISTRATION NO/DATE: SWISSMEDIC 63040 03.12.2013
1189916	SZ 2/2011	Austria		PRODUCT NAME: REGADENOSON UND DESSEN SALZE
2948455	PA2024513,C2948455	Lithuania		PRODUCT NAME: FEZOLINETANTAS; REGISTRATION NO/DATE: C(2023)8783 20231207
2428508	132020000000016	Italy		PRODUCT NAME: GILTERITINIB E SUOI SALI(XOSPATA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1399, 20191028
1280795	5/2016	Austria		PRODUCT NAME: ISAVUCONAZOL ALS ISAVUCONAZONIUMSULFAT ODER ALS EIN ISAVUCONAZONIUMSALZ MIT EINEM ANDEREN PHARMAZEUTISCH ANNEHMBAREN ANION, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, HYDRATS ODER SOLVATS; REGISTRATION NO/DATE: EU/1/15/1036 (MITTEILUNG) 20151015
2948455	2490014-4	Sweden		PRODUCT NAME: FEZOLINETANT; REG. NO/DATE: EU/1/23/1771 20231212
2428508	718	Finland

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Astellas

Astellas Competitive Landscape: Market Position, Strengths & Strategic Insights

Last updated: April 26, 2026

What is Astellas’ market position across key therapeutic areas?

Astellas is a global specialty biopharma focused on oncology, immunology, urology, and other high-value franchises, with notable presence in urology and oncology through marketed assets and platform-led pipeline execution. It operates with a research-to-commercial model that blends internal development with in-licensing and portfolio shaping via divestitures and acquisitions.

Revenue and scale (anchor points for competitive comparisons)

Metric	Directional read-through for competition	What it implies vs peers
Global specialty portfolio	Astellas competes head-to-head with larger category leaders and mid-tier specialists in urology and oncology	Price and access negotiations are constrained by payer evidence requirements
Commercial footprint	Broad hospital and specialty-channel reach	Stronger pull-through for oncology and urology products than smaller platform-only biotechs

Strategic implication: Astellas’ competitive advantage is less about broad “category dominance” and more about sustained execution in defined, data-heavy franchises where guideline inclusion and real-world adoption matter.

Which strengths drive Astellas’ competitive edge?

Astellas’ strength profile is anchored in portfolio focus, translational discipline, and operational execution supported by a global development and commercialization platform.

Strengths by competitive mechanism

Competitive mechanism	Astellas strength signal	Impact on rivals
Franchise focus	Concentration in oncology and urology reduces dilution of R&D attention	Direct threat to specialists that rely on single-asset bet profiles
Development discipline	Pipeline advancement emphasizes clinical differentiation and registrational readiness	Raises bar for follow-on entrants seeking incremental claims
Commercial execution	Specialty-channel support for key assets increases switching costs	Limits “me-too” penetration where payer inertia exists
Portfolio shaping	Ongoing buy-sell posture supports capital allocation to late-stage programs	Offloads non-core assets that would otherwise drain burn

How does Astellas’ pipeline positioning shape near-term competition?

Astellas’ pipeline posture matters because it determines the number and timing of “must-have” products that can defend incumbency or open payer conversations ahead of competitors’ launches.

Competitive pipeline structure (typical Astellas playbook)

Pipeline segment	Competitive function	Why it matters in this landscape
Late-stage assets	Create launch windows and line-extension opportunities	Sets the timetable for payer formularies and hospital contracting
Translational platform programs	Feed multiple MoA candidates tied to biomarker and clinical endpoints	Improves odds of differentiation in crowded target classes
Expansion into adjacent indications	Extends addressable patient populations	Mitigates patent cliffs by increasing total treated volumes

Strategic implication: The most actionable competitive signal is the cadence of registrational readouts and the probability of label expansion that sustains payer coverage.

Where does Astellas face the highest competitive pressure?

Pressure clusters where targets are crowded and where safety, sequencing, and payer value arguments decide uptake. In oncology and urology, competitors win by combining clinical outcomes, convenience (oral dosing, schedules), and health-economic value.

Pressure map by category logic

Category	Common competitive weapons	Astellas exposure
Oncology	Overall survival or progression-free survival differentiation, combination strategy, biomarker selection	High because payer needs stronger differentiation in crowded MoA classes
Urology	Clinical efficacy with tolerability, dosing convenience, and guideline adoption	High because urology is crowded with mechanism and imaging/diagnostic adjuncts
Immunology (where relevant)	Long-term safety and durable response claims	Medium, tied to pipeline depth and trial outcomes

What strategic insights matter for R&D decision-making?

Astellas competes by mapping clinical claims to payer and guideline endpoints early. That shapes how competitors should design development programs and how investors should assess the quality of differentiation.

Actionable insights

1. Clinical differentiation must be decision-relevant, not statistically adequate. In oncology and urology, competitive advantage comes from endpoints that drive guideline placement and payer approvals, not just p-values.
2. Label expansion is a central defense tactic. The competitive race is not only first approval; it is maintaining coverage through additional indications, subpopulations, and line positioning.
3. Safety and quality-of-life data influence switching. Specialty drugs with chronic or recurrent use compete on tolerability, dosing convenience, and patient-reported outcomes where available.
4. Timing is as important as innovation. Even strong products can lose momentum if launch sequencing misses payer contracting cycles or key guideline update windows.

How should investors view Astellas relative to peer archetypes?

Astellas sits in a hybrid lane: not a pure large-cap generalist, not a single-asset biotech. That structural position affects capital allocation, risk profile, and likely strategic moves.

Peer comparison framework

Peer archetype	Typical strengths	Typical weakness	Where Astellas competes directly
Large-cap pharma	Broad commercialization, deep late-stage pipeline scale	Slower portfolio pruning	Urology and oncology launches needing strong evidence packages
Mid-cap specialty	Focused pipeline and faster decisions	Less commercial reach	Data-led specialty products where payer evidence matters
Platform biotechs	Innovative science and flexible trial design	Higher execution risk and funding volatility	Discovery-to-clinic races in target families with uncertain outcomes

Strategic implication: Astellas’ most consistent advantage is translating clinical differentiation into durable commercial adoption.

What do Astellas’ portfolio and corporate actions indicate about strategy?

Portfolio actions in specialty biopharma typically reflect a capital allocation stance: doubling down on programs where registrational probability and commercial value are highest, while exiting areas that dilute focus.

Strategy signals commonly embedded in Astellas’ approach

• Late-stage prioritization to reduce time-to-value.
• Selective external partnerships to fill pipeline gaps and accelerate timelines.
• Non-core divestitures to fund higher-confidence assets.

Business impact: Competitors planning head-to-head studies and investors underwriting timelines should treat portfolio actions as forward indicators of where Astellas will place trial risk and commercialization emphasis.

---

Key Takeaways

• Astellas’ competitive position is built on focused specialty execution in oncology and urology, where payer and guideline decisions dominate adoption.
• Its strengths concentrate on franchise continuity, translational discipline, and commercialization capabilities that raise switching costs.
• Competitive pressure peaks in crowded MoA spaces where differentiation must be decision-relevant for coverage and guideline inclusion.
• The most actionable R&D and investment signal is not just whether Astellas has pipeline assets, but whether it has registrational cadence and label-expansion pathways that sustain coverage across contracting cycles.

---

FAQs

1. What is Astellas’ primary competitive advantage in specialty pharma?
   It is the ability to convert clinical differentiation in oncology and urology into durable payer and guideline adoption through disciplined development and specialty commercialization.

2. Where is Astellas most exposed to competitive displacement?
   Crowded oncology and urology classes where competitors can match or exceed outcomes while offering stronger value arguments on safety, dosing convenience, and overall healthcare cost impact.

3. How should competitors interpret Astellas’ portfolio shaping?
   Portfolio actions typically indicate where Astellas is increasing development and commercialization commitment while reducing capital allocation to lower-confidence areas.

4. What endpoints matter most for competitive differentiation against Astellas?
   Endpoints that drive guideline placement and reimbursement decisions, with additional weight for safety, tolerability, and quality-of-life where relevant.

5. What is the best lens for investors assessing Astellas’ next 24 to 36 months?
   The pipeline’s registrational cadence and the likelihood of label expansion that sustains treated volumes through payer contracting and guideline update cycles.

---

References

[1] Astellas Pharma Inc. Corporate information and annual reporting materials. Astellas Pharma.
[2] Astellas Pharma Inc. Pipeline and product information. Astellas Pharma.
[3] FDA. Drug approvals and labeling database. U.S. Food and Drug Administration.
[4] EMA. European Public Assessment Reports and product information. European Medicines Agency.